Traders purchased shares of Allergan plc (NYSE:AGN) on weakness during trading hours on Monday. $144.73 million flowed into the stock on the tick-up and $85.74 million flowed out of the stock on the tick-down, for a money net flow of $58.99 million into the stock. Of all equities tracked, Allergan had the 9th highest net in-flow for the day. Allergan traded down ($2.69) for the day and closed at $166.27
Several analysts have weighed in on the company. Credit Suisse Group set a $214.00 price target on Allergan and gave the company a “buy” rating in a report on Monday, January 22nd. Vetr cut Allergan from a “hold” rating to a “sell” rating and set a $180.97 price target on the stock. in a report on Monday, January 22nd. Morgan Stanley reaffirmed a “buy” rating on shares of Allergan in a report on Wednesday, January 24th. Barclays raised Allergan from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $220.00 to $230.00 in a report on Monday, January 29th. They noted that the move was a valuation call. Finally, ValuEngine cut Allergan from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $224.02.
The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.06 and a current ratio of 1.16. The firm has a market cap of $57,918.27, a PE ratio of -12.19, a P/E/G ratio of 1.17 and a beta of 1.29.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period last year, the company earned $3.90 EPS. Allergan’s revenue for the quarter was up 12.0% compared to the same quarter last year. equities analysts forecast that Allergan plc will post 15.58 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.76%. This is a positive change from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s dividend payout ratio (DPR) is presently -21.46%.
In related news, insider William Meury sold 58,879 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Maria Teresa Hilado purchased 895 shares of Allergan stock in a transaction that occurred on Thursday, March 15th. The shares were bought at an average price of $167.39 per share, for a total transaction of $149,814.05. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 8,095 shares of company stock worth $1,258,081. 0.36% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Prosight Management LP bought a new position in Allergan during the 4th quarter worth approximately $16,031,000. Tower Research Capital LLC TRC grew its position in shares of Allergan by 479.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock worth $289,000 after buying an additional 1,463 shares during the last quarter. Peloton Wealth Strategists grew its position in shares of Allergan by 37.1% in the 3rd quarter. Peloton Wealth Strategists now owns 10,485 shares of the company’s stock worth $2,149,000 after buying an additional 2,835 shares during the last quarter. Vantage Financial Partners Ltd. Inc. grew its position in shares of Allergan by 23.8% in the 4th quarter. Vantage Financial Partners Ltd. Inc. now owns 6,250 shares of the company’s stock worth $1,018,000 after buying an additional 1,200 shares during the last quarter. Finally, Canyon Capital Advisors LLC grew its position in shares of Allergan by 248.4% in the 4th quarter. Canyon Capital Advisors LLC now owns 501,494 shares of the company’s stock worth $82,034,000 after buying an additional 357,559 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.